SG11202011502VA - Methods of treating patients at risk for renal injury and renal failure - Google Patents

Methods of treating patients at risk for renal injury and renal failure

Info

Publication number
SG11202011502VA
SG11202011502VA SG11202011502VA SG11202011502VA SG11202011502VA SG 11202011502V A SG11202011502V A SG 11202011502VA SG 11202011502V A SG11202011502V A SG 11202011502VA SG 11202011502V A SG11202011502V A SG 11202011502VA SG 11202011502V A SG11202011502V A SG 11202011502VA
Authority
SG
Singapore
Prior art keywords
renal
risk
methods
treating patients
injury
Prior art date
Application number
SG11202011502VA
Inventor
Richard A Zager
Donald Jeffrey Keyser
Alvaro F Guillem
Original Assignee
Renibus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renibus Therapeutics Inc filed Critical Renibus Therapeutics Inc
Publication of SG11202011502VA publication Critical patent/SG11202011502VA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
SG11202011502VA 2018-05-24 2019-05-24 Methods of treating patients at risk for renal injury and renal failure SG11202011502VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676157P 2018-05-24 2018-05-24
US201862715508P 2018-08-07 2018-08-07
PCT/US2019/034018 WO2019227055A1 (en) 2018-05-24 2019-05-24 Methods of treating patients at risk for renal injury and renal failure

Publications (1)

Publication Number Publication Date
SG11202011502VA true SG11202011502VA (en) 2020-12-30

Family

ID=66867810

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011502VA SG11202011502VA (en) 2018-05-24 2019-05-24 Methods of treating patients at risk for renal injury and renal failure

Country Status (13)

Country Link
US (1) US11435364B2 (en)
EP (1) EP3803409A1 (en)
JP (1) JP2021526221A (en)
KR (1) KR20210019459A (en)
CN (1) CN112384807A (en)
AU (1) AU2019272960A1 (en)
BR (1) BR112020023943A2 (en)
CA (1) CA3101470A1 (en)
IL (1) IL278925A (en)
MX (1) MX2020012637A (en)
SG (1) SG11202011502VA (en)
WO (1) WO2019227055A1 (en)
ZA (1) ZA202007317B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4125860A4 (en) * 2020-03-23 2024-04-03 Renibus Therapeutics Inc Stress test and treatment of chronic kidney disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
JP4923146B2 (en) 2008-01-11 2012-04-25 リアタ ファーマシューティカルズ インコーポレイテッド Synthetic triterpenoids and methods of use in the treatment of disease
EP2324354B1 (en) 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
CN104391116B (en) 2008-10-21 2016-09-07 阿斯图特医药公司 Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure
CN104330574B (en) 2008-11-10 2017-04-12 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5827226B2 (en) 2009-08-07 2015-12-02 アスチュート メディカル,インコーポレイテッド Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5775874B2 (en) * 2009-08-28 2015-09-09 アスチュート メディカル,インコーポレイテッド Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3070474A3 (en) 2010-02-26 2016-12-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2721907T3 (en) 2011-08-26 2019-08-06 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
EP2841945A4 (en) 2012-04-24 2016-04-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
ES2861393T3 (en) * 2012-04-27 2021-10-06 Reata Pharmaceuticals Inc 2,2-Difluoropropionamide derivatives of methyl bardoxolone, pharmaceutical compositions and polymorphs thereof for use in the treatment of certain conditions
CN105074466B (en) * 2013-01-17 2018-01-09 阿斯图特医药公司 methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20160039682A (en) 2013-08-07 2016-04-11 아스튜트 메디컬 인코포레이티드 Assays for timp2 having improved performance in biological samples
GB201317286D0 (en) * 2013-09-30 2013-11-13 Calscience Internat Ltd Composition and Use
MX2016005834A (en) 2013-11-06 2016-11-17 Astute Medical Inc Assays for igfbp7 having improved performance in biological samples.
EP3099380B1 (en) * 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US9375408B2 (en) * 2014-09-02 2016-06-28 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
EP3200582B1 (en) * 2014-09-29 2023-11-15 Fred Hutchinson Cancer Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers

Also Published As

Publication number Publication date
IL278925A (en) 2021-01-31
KR20210019459A (en) 2021-02-22
ZA202007317B (en) 2022-08-31
MX2020012637A (en) 2021-04-28
WO2019227055A1 (en) 2019-11-28
US11435364B2 (en) 2022-09-06
US20230314448A1 (en) 2023-10-05
CA3101470A1 (en) 2019-11-28
US20200057076A1 (en) 2020-02-20
AU2019272960A1 (en) 2020-12-10
JP2021526221A (en) 2021-09-30
EP3803409A1 (en) 2021-04-14
CN112384807A (en) 2021-02-19
BR112020023943A2 (en) 2021-02-09

Similar Documents

Publication Publication Date Title
IL276398A (en) Combination therapy for the treatment of mastocytosis
IL270956A (en) Methods of treating fabry patients having renal impairment
HK1257321A1 (en) Histotripsy therapy systems and methods for the treatment of brain tissue
IL276301A (en) System and method for patient engagement
PL3253443T3 (en) Apparatus for treatment of snoring and sleep apnoea
IL256256A (en) System and method for extracorporeal blood treatment
IL282871A (en) Systems and methods for skin treatment
IL274019A (en) System and method for prediction of medical treatment effect
IL288677A (en) Methods of treating fabry disease in patients having renal impairment
IL269083A (en) Methods for preventing and treating heart disease
HK1257240A1 (en) Medicine for preventing and treating tissue injury caused by abnormal fat deposition and use of the medicine
GB2583322B (en) Method for managing behavioral treatment therapy and devices thereof
IL282643A (en) Combination therapy for treatment of hematological diseases
EP3556388A4 (en) Method for preventing and treating pathological renal tissue injury
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
IL290770A (en) Compounds and methods for treating oxalate-related diseases
PL3731893T3 (en) Apparatus for extracorporeal blood treatment
IL284462A (en) Systems and methods for tissue treatment
ZA202007317B (en) Methods of treating patients at risk for renal injury and renal failure
IL276639A (en) Agents and methods for treating dysproliferative diseases
GB201706747D0 (en) Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients
GB202005231D0 (en) Method of mimimising patient risk
HK1257238A1 (en) Medicine for preventing and treating lipid kidney injury and use of the medicine
PL3431119T3 (en) Apparatus for extracorporeal treatment of blood
IL292186A (en) Compositions and methods for treating blood disorders